PNC-27
Quick summary
A synthetic peptide built from a segment of the p53 protein joined to a sequence that helps it enter cells. Research focus: p53–HDM2 binding and membrane interaction in cell lines. This page leads with SRP's low-and-slow starting dose.
Overview
A synthetic peptide built from a segment of the p53 protein joined to a sequence that helps it enter cells. It is studied in cell-line models of membrane interaction.
Looking for research material? Simple Research Peptides lists PNC-27 5mg for laboratory research use.
Mechanism
Contains a segment of p53 that binds HDM2. Studies report that it forms pores in cell membranes that express HDM2.
Research areas
- p53–HDM2 binding
- membrane interaction in cell lines
Storage & reconstitution
Supplied as a freeze-dried (lyophilized) powder in a sealed vial. Unopened vials are generally kept cold and away from light. Labs usually reconstitute it with bacteriostatic or sterile water, letting the liquid run down the vial wall and swirling gently instead of shaking. The solution is then kept refrigerated.
Recommended starting dose (low and slow)
| Starting dose | Low end of the studied range: 100 mcg; 100 mcg. |
|---|---|
| Frequency | Reported schedules: 100–500mcg daily (titrate). |
| Reconstitution | Examples: 30 mg vial + 3 mL water = 10 mg/mL; 30mg vial + 3mL diluent (as listed). |
Studied higher doses
Studies have used doses up to the amounts below. Higher doses can be dangerous. Whether a person can reach them safely depends on height, weight, activity level, training and pre-existing conditions. We recommend following the lower starting dose above, and contacting SRP with any questions.
| Highest amount reported in studies | Top of the studied range: 500 mcg; 500 mcg. These are range tops, not verified ceilings. |
|---|---|
| Step-up schedules reported | The amount is usually stepped up gradually ('titrated') but none of the ones read gives a step schedule. |
Route and timing
Route: Subcutaneous injection after reconstitution is the route most often described in research protocols.
Timing: Pending - to be added by SRP
Cycle length and repeat
Pending - to be added by SRP
Half-life
Approximate, for Bobby's review: Not well characterized in published research.
Side effects
Pending - to be added by SRP
Suggested bloodwork and monitoring
Draft, for Bobby's review: CBC and comprehensive metabolic panel (kidney and liver function, electrolytes) before starting and again after a few weeks.
Cautions
Pending - to be added by SRP
Reconstitution calculator
Math aid only. It converts the numbers you enter; it is not dosing advice. For research use only. Prefilled with this page's vial size, reconstitution and low-and-slow starting dose where known; change any value.
Frequently asked questions
What is PNC-27 studied for?
In research it is studied for p53–HDM2 binding and membrane interaction in cell lines. Contains a segment of p53 that binds HDM2.
How is PNC-27 given in research?
Subcutaneous injection after reconstitution is the route most often described in research protocols. See the dosing frequency block on this page for how often.
What amount should a researcher start with?
This page lists SRP's low-and-slow starting dose in the Recommended starting dose section. Higher amounts that appear in studies are listed separately with their safety context. Start with the lower dose and contact SRP with any questions.
Related peptides
Last updated: October 19, 2026